Alpine Immune Sciences (NASDAQ:ALPN) Earns Outperform Rating from Analysts at SVB Leerink

SVB Leerink assumed coverage on shares of Alpine Immune Sciences (NASDAQ:ALPNGet Rating) in a research note issued to investors on Monday, Marketbeat reports. The brokerage issued an outperform rating and a $15.00 price objective on the biotechnology company’s stock. SVB Leerink also issued estimates for Alpine Immune Sciences’ Q4 2022 earnings at ($0.34) EPS, FY2022 earnings at ($1.58) EPS, FY2023 earnings at ($1.31) EPS, FY2024 earnings at ($2.49) EPS, FY2025 earnings at ($2.99) EPS and FY2026 earnings at ($3.11) EPS.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright reduced their price target on Alpine Immune Sciences from $21.00 to $8.00 in a research note on Monday, October 24th. Oppenheimer dropped their price objective on Alpine Immune Sciences from $17.00 to $14.00 and set an outperform rating on the stock in a research report on Monday, October 24th. Finally, Wedbush increased their target price on Alpine Immune Sciences to $25.00 in a report on Thursday, September 15th.

Alpine Immune Sciences Stock Performance

Shares of ALPN stock opened at $6.27 on Monday. Alpine Immune Sciences has a fifty-two week low of $4.82 and a fifty-two week high of $14.40. The stock has a 50 day moving average price of $6.52 and a two-hundred day moving average price of $7.80. The company has a market capitalization of $190.61 million, a P/E ratio of -3.50 and a beta of 1.39.

Institutional Investors Weigh In On Alpine Immune Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC bought a new stake in Alpine Immune Sciences during the 2nd quarter valued at $39,000. Public Employees Retirement System of Ohio purchased a new stake in Alpine Immune Sciences during the 3rd quarter valued at about $35,000. BNP Paribas Arbitrage SNC grew its stake in Alpine Immune Sciences by 88.7% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 6,572 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 3,090 shares during the last quarter. American International Group Inc. lifted its holdings in shares of Alpine Immune Sciences by 26.8% in the 2nd quarter. American International Group Inc. now owns 7,310 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 1,543 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Alpine Immune Sciences by 23.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 1,697 shares during the period. 79.01% of the stock is owned by institutional investors.

About Alpine Immune Sciences

(Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

See Also

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.